SCOPOLAMINE TRANSDE

The Defense Logistics Agency awarded a firm-fixed-price delivery order, SPE2DP-26-F-7519, to DMS PHARMACEUTICAL GROUP INC, identified by CAGE code 1UNB0, for the procurement of 11 units of Scopolamine Transdermal (NSN 6505014562380) under the master contract SPE2DX-25-D-9900, with a total contract value of $720.28. The award was issued on July 14, 2026, and delivery is required by July 29, 2026, to the specified location at Fort Bragg, North Carolina, under FOB Destination terms, meaning the contractor bears all shipping costs and responsibilities. The item is part of the DLA’s Medical Supply Chain, administered through the Pharmacy Prime Vendor program, with inspection and acceptance performed by the Government at the point of delivery. Packaging requires traceable shipping methods only—Parcel Post is prohibited—and all shipments must be clearly marked with the contract and delivery order numbers along with the ship-to address, though no specific labeling standards like UCC-128 or MIL-STD-129 are formally cited. The contractor is a certified Small Business, Women-Owned Small Business, and Small Disadvantaged Business, triggering federal reporting obligations under FAR 19.1406 and the WOSB program. Payment is processed through the Defense Finance and Accounting Service in Columbus, Ohio, using a voucher-based system with no electronic invoicing platform specified. The contracting officer is Lisa Quinn, with administrative support provided by Shairy M. Cartagena, but no Contracting Officer’s Representative or Technical Representative is designated. No special requirements, security clearances, or subcontracting plans are explicitly outlined, and no formal attachments, evaluation factors, or MIL-STD references are included in the documentation. The total quantity is fixed with zero variance permitted, and the contract contains no options or extensions.